Advances in the Treatment of Intermediate and Posterior Uveitis

Samantha Fraser-Bell; Carlos Pavesio


Expert Rev Ophthalmol. 2008;3(4):449-456. 

In This Article

Five-year View

We are still looking for the magic bullet, a form of therapy that will be specific for the problem we are dealing with without causing side effects of any significance. The recent advances have taken us a step further and it is possible that the next 5 years will get us even closer. A better understanding of the role of proinflammatory mediators will result in the identification of new targets for specific therapy. New immunosuppressive agents with a better toxicity profile are also being tested and will be added to our therapeutic options. Topical therapy with a far superior penetration and intraocular effect and noninvasive, trans-scleral modalities of drug delivery are under investigation.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: